ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1374

Emerging Therapies for Managing Patients with Alport Syndrome: Online Medical Education Improves Knowledge and Confidence of Nephrologists

Session Information

Category: Educational Research

  • 800 Educational Research


  • Larkin, Amy, Medscape Education, New York, New York, United States
  • Blatherwick, Donald, Medscape Education, New York, New York, United States
  • Boutsalis, George, Medscape Education, New York, New York, United States
  • Kelepouris, Ellie, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States

As new therapies for Alport syndrome continue to progress through development, nephrologists need an increased understanding of these drugs. We sought to determine if online education for nephrologists could improve clinical knowledge and confidence in managing patients with Alport syndrome with current and emerging treatment strategies.


The continuing medical education (CME) activity was an online video panel discussion among 3 faculty on current and emerging strategies for the management of Alport syndrome. Three multiple-choice knowledge questions and 1 self-reported confidence question were presented both before and immediately after the CME activity. A repeated pairs pre-/post-assessment study design was used and a chi-square test (P <.05 is considered significant) assessed educational effect for each activity. Cramer's V was used to calculate the effect size (0.06-0.15 is a noticeable effect, 0.16-0.26 considerable, and >0.26 extensive). The activity launched online on March 1, 2019, and data were collected through April 2, 2019.


Overall, knowledge and confidence improved among nephrologists (n = 71, V=.348, P<.001) from pre- to post-assessment:
24% demonstrated improved understanding of important factors when prescribing renin-angiotensin-aldosterone system (RAAS) inhibitors in patients with Alport syndrome (V=.216 (considerable educational impact), P<.05)
32% demonstrated improved recognition of efficacy data for bardoxolone methyl in Alport syndrome increase in the number of nephrologists (V=.297 (extensive educational impact), P<.001)
63% demonstrated improved identification of adverse effects for emerging treatments for Alport syndrome (V=.581 (extensive educational impact), P<.001)
38% reported increased confidence in understanding of role that chronic renal inflammation plays in AS

Continued educational gaps:
41% failed to recognize impact of bardoxolone methyl on Alport syndrome
20% did not recognize important factors when prescribing RAAS inhibitors in patients with Alport syndrome


The online video panel discussion CME activity demonstrated success in improving knowledge and confidence of nephrologists related to current and emerging therapies for the management of Alport syndrome. Continued knowledge gaps were identified for future educational targets.


  • Commercial Support